2015/01/15

バイオ医薬品の生産に関してサノフィとベーリンガーが戦略提携を発表

Sanofi Enters Strategic Manufacturing Collaboration with
Boehringer Ingelheim To Produce Biologics

Sanofi announced today it has entered into a strategic agreement with Boehringer Ingelheim for the manufacture of therapeutic monoclonal antibodies to reinforce Sanofi's manufacturing capacity to support upcoming product launches. Today, 72 percent of Sanofi's Research and Development projects are in biologics, nearly half of which are monoclonal antibodies (mAbs). 

Under the terms of the agreement, Sanofi will have access to Boehringer Ingelheim's capabilities in Biberach an der Riss, Germany to transfer and manufacture therapeutic mAbs. Initial product transfers will begin in early 2015. Financial terms were not disclosed.